Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
NASDAQ:IONS ) shareholders might be concerned after seeing the share price drop 24% in the last quarter. But don't let that distract from the very nice return generated over three years. After all, the share price is up a market-beating 30% in that time. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. Given that Ionis Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. In the last 3 years Ionis Pharmaceuticals saw its revenue shrink by 0.5% per year. Despite the lack of revenue growth, the stock has returned 9%, compound, over three years. Unless the company is going to make profits soon, we would be pretty cautious about
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal [Yahoo! Finance]Yahoo! Finance
- Ionis and Ono announce global license agreement for sapablursen in polycythemia veraBusiness Wire
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at JPMorgan Chase & Co. from $51.00 to $47.00. They now have a "neutral" rating on the stock.MarketBeat
- WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathyBusiness Wire
- Ionis to present at upcoming investor conferences [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 2/19/25 - Beat
IONS
Sec Filings
- 3/12/25 - Form 8-K
- 3/11/25 - Form 144
- 3/4/25 - Form 4
- IONS's page on the SEC website